Hologic (HOLX) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.98 per share a year ago.
Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company's shares down 5% after the bell on Wednesday.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close.
In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.
In the closing of the recent trading day, Hologic (HOLX) stood at $71.19, denoting a +1.17% change from the preceding trading day.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below.